Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) insider Jeffrey Hessekiel sold 15,106 shares of the firm's stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $52.62, for a total transaction of $794,877.72. Following the completion of the transaction, the insider owned 92,837 shares of the company's stock, valued at $4,885,082.94. This trade represents a 13.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Cytokinetics Trading Down 0.6%
Shares of Cytokinetics stock traded down $0.33 during trading on Wednesday, hitting $51.32. The stock had a trading volume of 1,594,452 shares, compared to its average volume of 2,118,581. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of -8.50 and a beta of 0.45. Cytokinetics, Incorporated has a 12 month low of $51.00 and a 12 month high of $88.31. The business's 50-day moving average is $63.25 and its 200 day moving average is $69.65.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.06. The business had revenue of $47.56 million for the quarter, compared to analysts' expectations of $41.88 million. Cytokinetics's quarterly revenue was up 2356.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.55) earnings per share. As a group, equities analysts expect that Cytokinetics, Incorporated will post -5.85 EPS for the current year.
Analyst Ratings Changes
CYTK has been the subject of several recent analyst reports. Royal Bank Of Canada boosted their price objective on Cytokinetics from $112.00 to $113.00 and gave the stock an "outperform" rating in a report on Thursday, October 8th. Leerink Partners lowered their target price on shares of Cytokinetics from $103.00 to $100.00 and set an "outperform" rating on the stock in a research note on Thursday, November 5th. Wall Street Zen upgraded shares of Cytokinetics from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Citizens Jmp lifted their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Finally, William Blair initiated coverage on shares of Cytokinetics in a research note on Friday, October 16th. They issued an "outperform" rating for the company. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $106.67.
View Our Latest Analysis on Cytokinetics
Institutional Investors Weigh In On Cytokinetics
A number of large investors have recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. boosted its stake in Cytokinetics by 810.2% in the third quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 397 shares in the last quarter. V Square Quantitative Management LLC grew its position in Cytokinetics by 71.5% during the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 191 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Cytokinetics during the second quarter worth approximately $36,000. Manchester Capital Management LLC purchased a new position in shares of Cytokinetics during the third quarter worth approximately $43,000. Finally, Allworth Financial LP lifted its holdings in shares of Cytokinetics by 35.6% in the 3rd quarter. Allworth Financial LP now owns 732 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 192 shares during the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytokinetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.
While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.